Why The Baudax Bio Stock Increased 32.38% (BXRX)

By Amit Chowdhry ● Jan 25, 2023
  • The stock price of Baudax Bio (BXRX) increased by 32.38% in the most recent trading session. This is why.

The stock price of Baudax Bio (BXRX) increased by 32.38% in the most recent trading session.

Why: Baudax Bio announced the successful outcome of its first interim analysis in a Phase II trial of BX1000 for neuromuscular blockade (NMB) in patients undergoing elective surgery.

This randomized, double-blind, active-controlled clinical trial comparing three different doses of BX1000 to a standard dose of rocuronium is planned to enroll a total of 80 adult patients undergoing elective surgery utilizing total intravenous anesthesia. And the primary efficacy endpoint is the proportion of patients meeting the criteria for Good or Excellent intubating conditions using a standardized scale. Plus the trial is evaluating the safety and tolerability profile of BX1000 and rocuronium in this patient population.

This pre-planned interim analysis evaluated the intubating conditions for each patient after the administration of the study drug in a blinded fashion. In the 20-patient cohort, 5 patients per group received one of the study medications. And all 20 patients were observed to have met the criteria for Good or Excellent intubating conditions at 60 seconds.

And 19 of the subjects were successfully intubated following the assessment at 60 seconds, and the one remaining subject following the assessment at 90 seconds. Study treatments were generally well tolerated with no occurrence of severe or serious adverse events.

This blinded interim analysis did not result in the decision to drop any of the four study groups nor any decision to adjust planned study enrollment numbers.

KEY QUOTE:

“We are encouraged by the results of the first interim analysis of the BX1000 Phase II surgery trial. We believe the use of BX1000, combined with our reversal agent, BX3000, could make for precise control of timing under neuromuscular paralysis for surgical patients, which could result in time and cost savings for patients and hospitals alike. We look forward to completing enrollment in the study in Q1 and sharing topline results for the study in April 2023.”

  • Gerri Henwood, Baudax Bio’s President and Chief Executive Officer